secwatch.observer — SEC 8-K summary
======================================

Issuer:     DICE Therapeutics, Inc. (—)
CIK:        0001645569
Form:       8-K
Filed at:   2023-06-07T23:59:59+00:00
Accession:  0000950170-23-026821
Event type: other
Sentiment:  neutral
Materiality: 0.15
Item codes: 5.03, 5.07, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

DICE Therapeutics stockholders approve officer exculpation amendment, elect directors
--------------------------------------------------------------------------------

- Approved Amended and Restated Certificate of Incorporation to permit officer exculpation: 40,311,115 for, 1,282,156 against.
- Class II directors elected: Jim Scopa (32,540,055 for) and Jake Simson, Ph.D. (32,596,683 for).
- Ratified Ernst & Young as independent auditor for FY2023: 45,245,715 for, 3,113 against.
- Amendment filed with Delaware Secretary of State on June 7, 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1645569/000095017023026821/0000950170-23-026821-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1645569/000095017023026821/dice-20230607.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-026821

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer